Bradley A. Connor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bradley A. Connor has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Davidson H Hamer
Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
3 shared publicationsMarina Rogova
The New York Center for Travel and Tropical Medicine, New York
3 shared publicationsMark S. Riddle
University of Nevada, Reno School of Medicine, Reno, Nevada, USA
3 shared publicationsDorottya Nagy-Szakal
Biotia, Inc, New York, New York
2 shared publications- Hilmir Asgeirsson
Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
2 shared publications - Lin Hwei Chen
Division of Infectious Diseases, Department of Medicine, Mount Auburn Hospital , Cambridge, Massachusetts
2 shared publications
Latest Publications
- Open Access
- 24 September 2022
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 29 (8)
Is standby therapy for Covid-19 a practical option for travellers?
Covid-19 vaccines and therapeutics developed through remarkable efforts have helped bolster public confidence to reopen the world and to restart travel. 1 Covid-19 vaccines on the World Health Organization Emergency Use Listing [Covid-19 Vaccines with WHO Emergency Use Listing. Available at: https://extranet.who.int/pqweb/vaccines/vaccinescovid-19-vaccine-eul-issued] are generally—but not always—accepted by many countries and jurisdictions. Many countries have imposed vaccine requirements for travel, which have evolved over time. The emergence of SARS-CoV-2 variants and the ‘immune escape’ that they exhibit have introduced concern about potential decline of protection from Covid-19 vaccines. 2
- 24 September 2022
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 29 (8)
Open AccessIs standby therapy for Covid-19 a practical option for travellers?
Covid-19 vaccines and therapeutics developed through remarkable efforts have helped bolster public confidence to reopen the world and to restart travel. 1 Covid-19 vaccines on the World Health Organization Emergency Use Listing [Covid-19 Vaccines with WHO Emergency Use Listing. Available at: https://extranet.who.int/pqweb/vaccines/vaccinescovid-19-vaccine-eul-issued] are generally—but not always—accepted by many countries and jurisdictions. Many countries have imposed vaccine requirements for travel, which have evolved over time. The emergence of SARS-CoV-2 variants and the ‘immune escape’ that they exhibit have introduced concern about potential decline of protection from Covid-19 vaccines. 2
- Open Access
- 18 March 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (3) , e223073
Comparative Effectiveness of Single vs Repeated Rapid SARS-CoV-2 Antigen Testing Among Asymptomatic Individuals in a Workplace Setting
The gold standard for diagnostic testing for SARS-CoV-2 is real-time reverse transcriptase–polymerase chain reaction (RT-qPCR).1 Because of lag times in obtaining results and the expense of this diagnostic modality, rapid antigen testing has been frequently used for screening of asymptomatic populations instead.2 Several SARS-CoV-2 rapid antigen tests are available in the US with Emergency Use Authorization by the US Food and Drug Administration based on data from symptomatic patients.3 Although rapid antigen tests have been criticized for poor sensitivity and specificity when screening asymptomatic patients, a knowledge gap still remains regarding the utility of these tests for screening.4 Given the large cohort of individuals being screened by an international service company based in New York City, we sought to analyze the comparative effectiveness and estimated accuracy of an employee screening program using single vs repeated antigen tests compared with RT-qPCR among asymptomatic individuals.
- 18 March 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (3) , e223073
Open AccessComparative Effectiveness of Single vs Repeated Rapid SARS-CoV-2 Antigen Testing Among Asymptomatic Individuals in a Workplace Setting
The gold standard for diagnostic testing for SARS-CoV-2 is real-time reverse transcriptase–polymerase chain reaction (RT-qPCR).1 Because of lag times in obtaining results and the expense of this diagnostic modality, rapid antigen testing has been frequently used for screening of asymptomatic populations instead.2 Several SARS-CoV-2 rapid antigen tests are available in the US with Emergency Use Authorization by the US Food and Drug Administration based on data from symptomatic patients.3 Although rapid antigen tests have been criticized for poor sensitivity and specificity when screening asymptomatic patients, a knowledge gap still remains regarding the utility of these tests for screening.4 Given the large cohort of individuals being screened by an international service company based in New York City, we sought to analyze the comparative effectiveness and estimated accuracy of an employee screening program using single vs repeated antigen tests compared with RT-qPCR among asymptomatic individuals.
- Open Access
- 3 February 2022
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 29 (2)
Acute hepatitis A in international travellers: a GeoSentinel analysis, 2008–2020
Non-immune international travellers are at risk of acquiring hepatitis A. Although hepatitis A vaccination is recommended for unvaccinated travellers to high or intermediate hepatitis A virus endemicity, compliance with this recommendation is not universal. The main objective was to describe the demographic and travel characteristics of international travellers infected with hepatitis A during travel. Available data on travellers with confirmed (positive molecular test) or probable (symptomatic individuals with a single positive IgM test) hepatitis A diagnosed during and after travel from January 2008 to December 2020 were obtained from the GeoSentinel Surveillance Network database. We analysed demographic and travel characteristics of infected travellers. Among 254 travellers with hepatitis A (185 confirmed and 69 probable), the median age was 28 years (interquartile range: 19–40), 150 (59%) were male, and among 54 travellers with information available, 53 (98%) were unvaccinated. The most common reasons for travel included tourism (n = 120; 47%) and visiting friends or relatives (VFR; n = 72; 28%). About two-thirds of VFR travellers with hepatitis A (n = 50; 69%) were younger than 20 years old. Hepatitis A was acquired most frequently in South-Central Asia (n = 63; 25%) and sub-Saharan Africa (n = 61; 24%), but 16 travellers (6%) acquired hepatitis A in regions with low endemicity including Western Europe (n = 7; 3%), the Caribbean (n = 6; 2%) and North America (n = 3; 1%). Median duration from illness onset to GeoSentinel site presentation was ~7 days (interquartile range : 4–14 days). Among 88 travellers with information available, 59% were hospitalized. Despite availability of highly effective vaccines, travellers still acquire hepatitis A, even when traveling to low-endemicity destinations. Providing pre-departure hepatitis A vaccine to susceptible travellers is crucial to reducing travel-associated hepatitis A and should be offered to all travellers as part of the pre-travel consultation, regardless of destination.
- 3 February 2022
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 29 (2)
Open AccessAcute hepatitis A in international travellers: a GeoSentinel analysis, 2008–2020
Non-immune international travellers are at risk of acquiring hepatitis A. Although hepatitis A vaccination is recommended for unvaccinated travellers to high or intermediate hepatitis A virus endemicity, compliance with this recommendation is not universal. The main objective was to describe the demographic and travel characteristics of international travellers infected with hepatitis A during travel. Available data on travellers with confirmed (positive molecular test) or probable (symptomatic individuals with a single positive IgM test) hepatitis A diagnosed during and after travel from January 2008 to December 2020 were obtained from the GeoSentinel Surveillance Network database. We analysed demographic and travel characteristics of infected travellers. Among 254 travellers with hepatitis A (185 confirmed and 69 probable), the median age was 28 years (interquartile range: 19–40), 150 (59%) were male, and among 54 travellers with information available, 53 (98%) were unvaccinated. The most common reasons for travel included tourism (n = 120; 47%) and visiting friends or relatives (VFR; n = 72; 28%). About two-thirds of VFR travellers with hepatitis A (n = 50; 69%) were younger than 20 years old. Hepatitis A was acquired most frequently in South-Central Asia (n = 63; 25%) and sub-Saharan Africa (n = 61; 24%), but 16 travellers (6%) acquired hepatitis A in regions with low endemicity including Western Europe (n = 7; 3%), the Caribbean (n = 6; 2%) and North America (n = 3; 1%). Median duration from illness onset to GeoSentinel site presentation was ~7 days (interquartile range : 4–14 days). Among 88 travellers with information available, 59% were hospitalized. Despite availability of highly effective vaccines, travellers still acquire hepatitis A, even when traveling to low-endemicity destinations. Providing pre-departure hepatitis A vaccine to susceptible travellers is crucial to reducing travel-associated hepatitis A and should be offered to all travellers as part of the pre-travel consultation, regardless of destination.
- Open Access
- 1 September 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 110, 232-234
Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case
- 1 September 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 110, 232-234
Open AccessMonoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case
- 28 August 2020
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 28 (2)
What will travel medicine look like in the COVID-19 pandemic era?
Travel medicine has virtually stopped in light of the coronavirus pandemic. It is worth contemplating how travel medicine will be affected by the ongoing pandemic when international travel starts to become more possible. How will we advise patients and use the coming vaccines that may be available? Travel medicine practices are well-suited to play a major role in advising travellers in the pandemic era.
- 28 August 2020
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 28 (2)
What will travel medicine look like in the COVID-19 pandemic era?
Travel medicine has virtually stopped in light of the coronavirus pandemic. It is worth contemplating how travel medicine will be affected by the ongoing pandemic when international travel starts to become more possible. How will we advise patients and use the coming vaccines that may be available? Travel medicine practices are well-suited to play a major role in advising travellers in the pandemic era.
- 16 June 2020
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 115 (10) , 1553-1555
Use of the Multiplex Diagnostic PCR Panel in Diarrheal Disease: Expert Guidance on the Interpretation of Results With a Focus on Travelers' Diarrhea
- 16 June 2020
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 115 (10) , 1553-1555
Use of the Multiplex Diagnostic PCR Panel in Diarrheal Disease: Expert Guidance on the Interpretation of Results With a Focus on Travelers' Diarrhea
- Open Access
- 21 February 2020
- Published by Springer Nature in International Journal of Emergency Medicine
- Vol. 13 (1) , 1-5
A dignitary medicine curriculum developed using a modified Delphi methodology
Background: Dignitary medicine is an emerging field of training that involves the specialized care of diplomats, heads of state, and other high-ranking officials. In an effort to provide guidance on training in this nascent field, we convened a panel of experts in dignitary medicine and using the Delphi methodology, created a consensus curriculum for training in dignitary medicine.Methods: A three-round Delphi consensus process was performed with 42 experts in the field of dignitary medicine. Predetermined scores were required for an aspect of the curriculum to advance to the next round. The scores on the final round were used to determine the components of the curriculum. Scores below the threshold to advance were dropped in the subsequent round.Results: Our panel had a high degree of agreement on the required skills needed to practice dignitary medicine, with active practice in a provider’s baseline specialty, current board certification, and skills in emergency care and resuscitation being the highest rated skills dignitary medicine physicians need. Skills related to vascular and emergency ultrasound and quality improvement were rated the lowest in the Delphi analysis. No skills were dropped from consideration.Conclusions: The results of our work can form the basis of formal fellowship training, continuing medical education, and publications in the field of dignitary medicine. It is clear that active medical practice and knowledge of resuscitation and emergency care are critical skills in this field, making emergency medicine physicians well suited to practicing dignitary medicine.
- 21 February 2020
- Published by Springer Nature in International Journal of Emergency Medicine
- Vol. 13 (1) , 1-5
Open AccessA dignitary medicine curriculum developed using a modified Delphi methodology
Background: Dignitary medicine is an emerging field of training that involves the specialized care of diplomats, heads of state, and other high-ranking officials. In an effort to provide guidance on training in this nascent field, we convened a panel of experts in dignitary medicine and using the Delphi methodology, created a consensus curriculum for training in dignitary medicine.Methods: A three-round Delphi consensus process was performed with 42 experts in the field of dignitary medicine. Predetermined scores were required for an aspect of the curriculum to advance to the next round. The scores on the final round were used to determine the components of the curriculum. Scores below the threshold to advance were dropped in the subsequent round.Results: Our panel had a high degree of agreement on the required skills needed to practice dignitary medicine, with active practice in a provider’s baseline specialty, current board certification, and skills in emergency care and resuscitation being the highest rated skills dignitary medicine physicians need. Skills related to vascular and emergency ultrasound and quality improvement were rated the lowest in the Delphi analysis. No skills were dropped from consideration.Conclusions: The results of our work can form the basis of formal fellowship training, continuing medical education, and publications in the field of dignitary medicine. It is clear that active medical practice and knowledge of resuscitation and emergency care are critical skills in this field, making emergency medicine physicians well suited to practicing dignitary medicine.
- Open Access
- 4 December 2019
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 26 (8)
Cholera in travellers: a systematic review
Exposure to cholera is a risk for individuals and groups travelling to endemic areas, and the bacteria can be imported to cholera-free countries by returning travellers. This systematic review of the literature describes the circumstances in which cholera infection can occur in travellers and considers the possible value of the cholera vaccine for prevention in travellers. PubMed and EMBASE were searched for case reports of cholera or diarrhoea among travellers, with date limits of 1 January 1990–30 April 2018. Search results were screened to exclude the following articles: diarrhoea not caused by cholera, cholera in animals, intentional cholera infection in humans, non-English articles and publications on epidemics that did not report clinical details of individual cases and publications of cases pre-dating 1990. Articles were reviewed through descriptive analytic methods and information summarized. We identified 156 cases of cholera imported as a consequence of travel, and these were reviewed for type of traveller, source country, serogroup of cholera, treatment and outcomes. The case reports retrieved in the search did not report consistent levels of detail, making it difficult to synthesize data across reports and draw firm conclusions from the data. This clinical review sheds light on the paucity of actionable published data regarding the risk of cholera in travellers and identifies a number of gaps that should drive additional effort. Further information is needed to better inform evidence-based disease prevention strategies, including vaccination for travellers visiting areas of cholera risk. Modifications to current vaccination recommendations to include or exclude current or additional traveller populations may be considered as additional risk data become available. The protocol for this systematic review is registered with PROSPERO (registration number: 122797).
- 4 December 2019
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 26 (8)
Open AccessCholera in travellers: a systematic review
Exposure to cholera is a risk for individuals and groups travelling to endemic areas, and the bacteria can be imported to cholera-free countries by returning travellers. This systematic review of the literature describes the circumstances in which cholera infection can occur in travellers and considers the possible value of the cholera vaccine for prevention in travellers. PubMed and EMBASE were searched for case reports of cholera or diarrhoea among travellers, with date limits of 1 January 1990–30 April 2018. Search results were screened to exclude the following articles: diarrhoea not caused by cholera, cholera in animals, intentional cholera infection in humans, non-English articles and publications on epidemics that did not report clinical details of individual cases and publications of cases pre-dating 1990. Articles were reviewed through descriptive analytic methods and information summarized. We identified 156 cases of cholera imported as a consequence of travel, and these were reviewed for type of traveller, source country, serogroup of cholera, treatment and outcomes. The case reports retrieved in the search did not report consistent levels of detail, making it difficult to synthesize data across reports and draw firm conclusions from the data. This clinical review sheds light on the paucity of actionable published data regarding the risk of cholera in travellers and identifies a number of gaps that should drive additional effort. Further information is needed to better inform evidence-based disease prevention strategies, including vaccination for travellers visiting areas of cholera risk. Modifications to current vaccination recommendations to include or exclude current or additional traveller populations may be considered as additional risk data become available. The protocol for this systematic review is registered with PROSPERO (registration number: 122797).
- Open Access
- 30 July 2019
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 26 (8)
Cutaneous and mucocutaneous leishmaniasis in travellers and migrants: a 20-year GeoSentinel Surveillance Network analysis
Cutaneous leishmaniasis (CL) may be emerging among international travellers and migrants. Limited data exist on mucocutaneous leishmaniasis (MCL) in travellers. We describe the epidemiology of travel-associated CL and MCL among international travellers and immigrants over a 20-year period through descriptive analysis of GeoSentinel data. Demographic and travel-related data on returned international travellers diagnosed with CL or MCL at a GeoSentinel Surveillance Network site between 1 September 1997 and 31 August 2017 were analysed. A total of 955 returned travellers or migrants were diagnosed with travel-acquired CL (n = 916) or MCL during the study period, of whom 10% (n = 97) were migrants. For the 858 non-migrant travellers, common source countries were Bolivia (n = 156, 18.2%) and Costa Rica (n = 97, 11.3%), while for migrants, they were Syria (n = 34, 35%) and Afghanistan (n = 22, 22.7%). A total of 99 travellers (10%) acquired their disease on trips of ≤ 2 weeks. Of 274 cases for which species identification was available, Leishmania Viannia braziliensis was the most well-represented strain (n = 117, 42.7%), followed by L. major (n = 40, 14.6%) and L. V. panamensis (n = 38, 13.9%). Forty cases of MCL occurred, most commonly in tourists (n = 29, 72.5%) and from Bolivia (n = 18, 45%). A total of 10% of MCL cases were acquired in the Old World. Among GeoSentinel reporting sites, CL is predominantly a disease of tourists travelling mostly to countries in Central and South America such as Bolivia where risk of acquiring L. V. braziliensis and subsequent MCL is high. The finding that some travellers acquired leishmaniasis on trips of short duration challenges the common notion that CL is a disease of prolonged travel. Migrants from areas of conflict and political instability, such as Afghanistan and Syria, were well represented, suggesting that as mass migration of refugees continues, CL will be increasingly encountered in intake countries.
- 30 July 2019
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 26 (8)
Open AccessCutaneous and mucocutaneous leishmaniasis in travellers and migrants: a 20-year GeoSentinel Surveillance Network analysis
Cutaneous leishmaniasis (CL) may be emerging among international travellers and migrants. Limited data exist on mucocutaneous leishmaniasis (MCL) in travellers. We describe the epidemiology of travel-associated CL and MCL among international travellers and immigrants over a 20-year period through descriptive analysis of GeoSentinel data. Demographic and travel-related data on returned international travellers diagnosed with CL or MCL at a GeoSentinel Surveillance Network site between 1 September 1997 and 31 August 2017 were analysed. A total of 955 returned travellers or migrants were diagnosed with travel-acquired CL (n = 916) or MCL during the study period, of whom 10% (n = 97) were migrants. For the 858 non-migrant travellers, common source countries were Bolivia (n = 156, 18.2%) and Costa Rica (n = 97, 11.3%), while for migrants, they were Syria (n = 34, 35%) and Afghanistan (n = 22, 22.7%). A total of 99 travellers (10%) acquired their disease on trips of ≤ 2 weeks. Of 274 cases for which species identification was available, Leishmania Viannia braziliensis was the most well-represented strain (n = 117, 42.7%), followed by L. major (n = 40, 14.6%) and L. V. panamensis (n = 38, 13.9%). Forty cases of MCL occurred, most commonly in tourists (n = 29, 72.5%) and from Bolivia (n = 18, 45%). A total of 10% of MCL cases were acquired in the Old World. Among GeoSentinel reporting sites, CL is predominantly a disease of tourists travelling mostly to countries in Central and South America such as Bolivia where risk of acquiring L. V. braziliensis and subsequent MCL is high. The finding that some travellers acquired leishmaniasis on trips of short duration challenges the common notion that CL is a disease of prolonged travel. Migrants from areas of conflict and political instability, such as Afghanistan and Syria, were well represented, suggesting that as mass migration of refugees continues, CL will be increasingly encountered in intake countries.
- Open Access
- 9 April 2018
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 25 (1)
Do prebiotics reduce the risk of travellers' diarrhoea? Promising but more research needed
To the Editor-in-Chief
- 9 April 2018
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 25 (1)
Open AccessDo prebiotics reduce the risk of travellers' diarrhoea? Promising but more research needed
To the Editor-in-Chief